SAN DIEGO--(BUSINESS WIRE)--MicroPhage announced today the launch of its new diagnostic platform at the 110th Annual General Meeting of the American Society for Microbiology (ASM) in San Diego. The Company’s initial commercial product is designed to rapidly identify Staphylococcus aureus (“staph”) bacteria as well as determine methicillin resistance (MRSA) or susceptibility (MSSA) in suspected cases of bloodstream infections in as little as five hours. Today’s standard of care for determining these types of infections takes up to three days for test-results, which can lead to ineffectual treatment and death. The product is CE-Marked for sale outside the United States and U.S. Food and Drug Administration (FDA) review is pending.
